RYTMRHYTHM PHARMACEUTICALS, INC.

Nasdaq rhythmtx.com


$ 38.47 $ -0.42 (-1.08 %)    

Thursday, 09-May-2024 15:59:58 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 38.5
$ 39.01
$ 0.00 x 0
$ 0.00 x 0
$ 37.95 - $ 39.16
$ 15.50 - $ 52.57
467,414
na
2.35B
$ 1.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-01-2023 06-30-2023 10-Q
5 05-02-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-03-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-03-2021 06-30-2021 10-Q
13 05-03-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-02-2020 09-30-2020 10-Q
16 08-03-2020 06-30-2020 10-Q
17 05-04-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-01-2019 09-30-2019 10-Q
20 07-29-2019 06-30-2019 10-Q
21 05-03-2019 03-31-2019 10-Q
22 03-08-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-12-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 canaccord-genuity-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-79

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target...

 b-of-a-securities-downgrades-rhythm-pharmaceuticals-to-neutral-lowers-price-target-to-42

B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the pr...

 needham-maintains-buy-on-rhythm-pharmaceuticals-lowers-price-target-to-46

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $...

 rhythm-pharmaceuticals-presents-data-from-phase-3-pediatrics-trial-at-pediatric-endocrine-society-annual-meeting

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z s...

 rhythm-pharmaceuticals-announces-publication-of-results-from-phase-2-study-of-setmelanotide-for-the-treatment-of-hypothalamic-obesity-in-the-lancet-diabetes--endocrinology

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks...

 needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

 jim-cramer-is-willing-to-let-this-pharma-stock-catch-fire-advises-not-to-sell-mckesson

The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.

 wells-fargo-maintains-overweight-on-rhythm-pharmaceuticals-lowers-price-target-to-52

Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price targ...

 needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

 rhythm-pharmaceuticals-announces-first-patient-dosed-in-phase-1-trial-evaluating-rm-718

- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce b...

 needham-reiterates-buy-on-rhythm-pharmaceuticals-maintains-50-price-target

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.

 rhythm-pharmaceuticals-q4-eps-070-misses-069-estimate-sales-2423m-miss-2538m-estimate

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate...

 earnings-scheduled-for-february-22-2024

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on reve...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION